The 6th Imric Retreat

WBP4 controls developmental splicing transitions required for normal brain maturation

Shiri Jaffe-Herman Ophir Geminder Eden Engal Adi Gershon Gillian Kay
Department of Biochemistry and Molecular Biology, The Hebrew University of Jerusalem, Israel

Increasing evidence links splicing dysregulation to neurodevelopmental delay (NDD), although the molecular mechanisms connecting the two remain unclear. An example of that connection was published by our lab, demonstrating that biallelic mutations in the spliceosome component WBP4 are associated with NDD. To investigate how altered splicing affects brain development in its native developmental context, we generated a Wbp4 knockout mouse model. As Wbp4 deficiency caused pre-weaning lethality, we performed RNA-seq on E15.5 forebrains from Wbp4-/- and Wbp4+/+ mice. Our findings indicate that WBP4 loss leads to molecular developmental delay. This was demonstrated by deconvolution analysis, which revealed reduced neuronal populations in Wbp4-/- forebrains and a strong negative correlation between mutant splicing patterns and normal developmental splicing transitions during mouse brain development, suggesting that the mutant brain is arrested at an earlier developmental stage. To extend these findings to humans, we used iPSC-derived neural progenitor cells from a WBP4-/- patient and parents, which showed splicing changes similar to those observed in mice. Cross-referencing with human iPSC neuronal differentiation data revealed that WBP4 loss results in splicing patterns characteristic of earlier developmental stages, consistent with the molecular developmental delay observed in vivo. Finally, we attempted to rescue the altered splicing patterns by modulating spliceosome function and achieved partial restoration in a subset of events. Together, these findings identify WBP4 as a conserved regulator of neurodevelopmental splicing programs, suggesting that disruption of these programs contributes to NDD, while highlighting spliceosome modulation as a potential therapeutic avenue for such disorders.